Peer Review History
| Original SubmissionJuly 15, 2020 |
|---|
|
PONE-D-20-21940 CoMA – an Intuitive and User-friendly Pipeline for Amplicon-Sequencing Data Analysis PLOS ONE Dear Mr. Hupfauf, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Oct. 1, 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Zechen Chong Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The manuscript by Hupfauf et al. describes COMA, a pipeline designed to the analysis of metabarcoding data. The paper is overall well written. However, there are some flaws that need to be addressed as illustrated below. Introduction: L77-78 The list of reference databases should be improved by including MIDORI, PR2 DB and ITSoneDB. Moreover authors should discuss the fact that actually both Greengenes and RDP are outdated. L 88. Authors should discuss the differences between OTU and ASV. They cite the paper by Callahan et al 2017 in Discussion but they did not describe the technical differences between the two approaches. L 126 454 was terminated in 2016. Table 1: Add PEMA M&M L 170-172 Authors stated in COMA a denoising and error correction step is implemented by using Lotus. It is not clear what they mean with “denoising and error correction”. Literally denoising is the procedure applied to remove the noise introduced by amplification and sequencing, as stated by Quince et al in the paper describing AmpliconNoise. Actually, the denoising procedures are strictly related to the used sequencing platform as well as different sequencing approaches are characterized by different error profiles. In the introduction, authors declare COMA is able to analyze Illumina, PacBio and Roche 454 data, consequently if a denoising step is implemented in the pipeline, it must take into account the different peculiarities of these sequencing approaches. Authors should clarify this point. L 176 The RDP-classifier is a Bayesian classifier inferring the posterior probability based on the known kmer distribution in genera and the observed one. Consequently it do not perform any alignment. Moreover it is not described how blast alignment is performed (default options?) and if it is filtered according to the observed similarity. L 230-343 My major concerns are related to both the choice and the analysis of Mock data. Concerning the selected mocks: i) the inclusion of a mock with few dominant taxa and other less abundant taxa could recapitulate a real condition in several cases; ii) in consideration that 454 has been discontinued the choice of a ITS mock obtained by 454 sequencing is not very useful nowadays. In the following some comments concerning the analysis of mock data. First of all by taking into account for each mock the mixed strains are known, it is possible to infer the expected amplicon sequences, by performing an in silico PCR on the reference genomes. This would also allow to measure the intra- and inter- generic sequence variability and compare the observed OTUs/ASVs with the expected sequences. Moreover, it is not completely clear how taxonomic assignment was performed with the different pipelines. While in COMA an alignment based approach was used (see comments above for related issues), in QIIME the author used the assign-taxonomy.py script which implements 5 different taxonomic assignment methods (including blast), but they do not indicate the used one (uclust is the default). The same issue is related to the taxonomic classification in Mothur while in QIIME2 a naïve-bayesian classifier trained on the same target region was used. Actually it seems different methods for taxonomic classification were applied and this may influence the comparison of the results. Moreover, the ASV inference pipeline implemented in QIIME2 is deeply influence by the used filtering parameters. Have the authors used the default parameters or have adjusted them according to the overall data quality? Finally, authors should indicate the versions of the used tools. Figure 2, 3 and 4 I suggest to change the colors in order to improve the plots. In general, I find the manuscript is too long and not focused. Indeed, it includes two messages: the description of a novel pipeline for DNA metabarcoding analysis, and an analysis of real data of soil samples. Maybe the Authors can consider to reduce the part concerning real data to the comparative aspects, moving the microbiome analysis of soil samples and its discussion to a different manuscript focused on this matter. Reviewer #2: This manuscript reported a pipeline CoMA for amplicon-sequencing data analysis. It reported that comparing to other command line tools, the pipeline CoMA's advantages are much easier, more user-friendly, compatible with any common operating system, and good performance compared. Major comments: 1. The CoMA is distributed by a 5.77GB VirtualBox .ova file. I cannot test it on my remote lab server because it doesn't have GUI to use VirtualBox. Due to COVID19, I couldn't access my high performance desktop computer in my office. I couldn't test it on my home laptop because of CoMA's large disk space requirement (50GB). Hence, I am sorry that I didn't test whether it can be the installed and work correctly. Hope other reviewers did that. In fact, I don't think it's an advantage to use virtual machine image for distributing CoMA. I think Docker is a much better and easier solution for both software maintainers and users. 2. As I didn't run CoMA by myself, so I didn't see it's graphical interface. However, according to the description in the manuscript and CoMA's manual online, I don't think its GTK+ dialog GUI is better than a command line interactive mode. I don't think command line is hard to use, and I don't think CoMA is easier and user-friendly than command line tools. 3. It reported that "the workflow results in highly esthetic and publication-ready graphics". However, I didn't find any example figure in the manuscript and CoMA's website. As I didn't run CoMA, so I cannot check how good the output figures are. I think the authors should provide a demo/tutorial or some example output figures on their website. 4. It reported that "we used various open-source, third-party tools and combined them into a linear analysis workflow in the form of a Bash script". Hence, I think the core of CoMA is just a bash script. I think the authors need to make their code available (maybe on GitHub) if CoMA is an open source software. 5. In addition, the authors didn't describe which tools are used in CoMA and in which steps they are used. In Figure 1, the main tools used in each step need to be marked. 6. It reported that the results generated by CoMA and QIIME were very similar. Is it because CoMA used QIIME in several key steps? 7. For Soil dataset, QIIME2 wasn't included in the comparison. Why? Minor comments: 1. Line 126, delete the space in the URL. Reviewer #3: The authors present a novel practical pipeline for processing of next-generation datasets for microbiome analyses. The modules in this pipelines range from QC to taxonomic assignment and clustering analysis. The pipeline also provides visualization and statistical analysis tools. The pipeline is bench-marked on multiple microbiome datasets such as soil, mock datasets. The experiments suggest that it outperforms other known methods in the field. The paper is well-written and is a good contribution to the community. A few minor concerns are: 1) A figure representing more details of the tasks (QC, taxonomic assignment) will be helpful. 2) One feature that is encouraged in the pipeline is to compare and validate across technologies. 3) With upcoming HiFi technology, there is a huge opportunity to perform strain-aware metagenome assembly. The computational methods like SDip (please cite https://doi.org/10.1101/2020.02.25.964445) can be explored for assembling microbiomes. This method has the potential to use variation from multiple strains and species to bin reads and perform assembly. A few sentences on third-generation technologies and analysis methods in the manuscript are appreciated. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-21940R1 CoMA – an intuitive and user-friendly pipeline for amplicon-sequencing data analysis PLOS ONE Dear Dr. Hupfauf, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please address Reviewer 1 and 2's comments, especially Reviewer 2's Error messages when testing the tool. Please submit your revised manuscript by Oct 31st, 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Zechen Chong Academic Editor PLOS ONE Additional Editor Comments (if provided): Please try the best to address Reviewer 1 and 2's comments, especially for reviewer 2's error messages when testing the tool. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: L 70 ITSoneDB is the correct name L 71-74 Please clarify what did you mean with “de novo assembling” L 170-172 Authors stated in COMA a denoising and error correction step is implemented by using Lotus. It is not clear what they mean with “denoising and error correction”. Literally denoising is the procedure applied to remove the noise introduced by amplification and sequencing, as stated by Quince et al in the paper describing AmpliconNoise. Actually, the denoising procedures are strictly related to the used sequencing platform as well as different sequencing approaches are characterized by different error profiles. In the introduction, authors declare COMA is able to analyze Illumina, PacBio and Roche 454 data, consequently if a denoising step is implemented in the pipeline, it must take into account the different peculiarities of these sequencing approaches. Authors should clarify this point. The quality filtering is done using LotuS, precisely the sdm tool. Regarding the LotuS publication (https://doi.org /10.1186/2049-2618-2-30), sdm “... filter(s) input sequences after average quality, accumulated error over the sequence, quality in a freely definable window and remove 5′ low-quality bases filtered for these criteria. Furthermore, sequences are filtered for min/max length, ambiguous nucleotides, max barcode and primer errors, polynucleotide runs, and trimmed for adapter sequences, if present.”. The reviewer is right in the sense that the filtering settings largely depend on the sequencing platform; hence, LotuS provides pre-adjusted sdm setting files for MiSeq, HiSeq, 454 and PacBio. The newest version of the CoMA pipeline now asks the user, which sequencing platform was used, and selects the corresponding sdm file for the sequence filtering process. Filtering and denoising are two different things. Based on the authors answer they performs filtering and not denoising. Please fix this point in the manuscript. Moreover, the ASV inference pipeline implemented in QIIME2 is deeply influence by the used filtering parameters. Have the authors used the default parameters or have adjusted them according to the overall data quality? Finally, authors should indicate the versions of the used tools. DONE. As for QIIME and Mothur, we also used the recommended settings for the QIIME2 analysis from the official SOP documentation. We are providing the applied versions of Mothur, QIIME and QIIME2 now in the manuscript; please see lines 260, 292 and 311. The QIIME2 SOP documentation the authors mentions are tutorials designed according to data characteristics and consequently may not work correctly on your data. Reviewer #2: The authors' responses and revisions addressed some of my comments in the last round of review. However, the most important comments were not well addressed. Generally, I think the core purpose of the manuscript is to introduce the new pipeline CoMA. So I think the comments focusing on the usability of the pipeline are the most important. 1. I suggested using Docker instead of VirtualBox .ova file to distribute the pipeline. I am glad that the authors agreed with my suggestion. They said they will develop "Docker image, a direct Linux installer as well as Singularity container" of CoMA and provide all code on GitHub soon (two or three weeks). However, I think all these things need to be well-prepared and described in the revised manuscript before this submission of revision. 2. It seems that the other two reviewers didn't test the CoMA VM in the last round of review either. Although the CoMA VM would cost a lot of my disk space, I think I should install and test it. However, the usability of CoMA is worse than I expected. 2.1. In the beginning, it couldn't work. I checked the log file and found there is a kind of conflict between my MacOS 10.15.6 and VirtualBox (https://forums.virtualbox.org/viewtopic.php?f=8&t=99739). Then I disabled the mic device in VirtualBox and it worked. Fortunately, it only took 19GB on my Mac instead of the 50GB suggested space. 2.2. Then I followed the CoMA manual to install usearch and then test it with the example data in CoMA VM https://www.uibk.ac.at/microbiology/services/manual-coma.pdf. I still don't agree that the GTK dialog is a user-friendly way. In fact, the CoMA GTK dialog doesn't provide more information than directly display and input in the command line terminal. It's even worse because I couldn't trace back all the parameters I inputted in the GTK dialog window. The pipeline output all the information to the terminal. The authors should redirect log information to separated log files of each tool, and keep the terminal only display a few main information. Besides, as I need to test several times with different choices, so I have to go through the whole dialog windows again and again. If it's a command-line tool, I can just write the whole command once and then copy&paste and modify some parameters. Therefore, I don't agree that GTK dialog is a good way even for entry-level users. 2.3. I ran the pipeline strictly following the manual. It showed that I successfully ran the project. Although I saw several "Error" information in the terminal and the final log file, I thought they were just "warnings", such as "Error: (1431.1) FASTA-Reader: Warning: FASTA-Reader: ". 2.4. However, I tried some other choices and caused some errors such as Python package biom terminated by "UnboundLocalError: local variable data_start referenced before assignment". The CoMA pipeline didn't show me any useful information about whether it's a software problem or caused by a wrong parameter I chose. The funny thing is that the pipeline still showed "Process succeeded!" even though the error happened. In fact, I found the pipeline totally doesn't do exception handling. It's unacceptable. 3. I still think it's necessary to revise Figure 1 to show the main tools or parameters in each main step of the pipeline. In fact, I checked the source code of the pipeline in CoMA VM. Besides the python code for plotting and generating reports, there is not much code for the main steps of the pipeline. Therefore, it shouldn't be a problem to illustrate more detail of the main steps of the pipeline in one figure. And it's worth doing. 4. In fact, I agree with Reviewer #1's comment that the manuscript is too long and not focused. The authors should describe more details of the pipeline, such as the key parameters used in each step, instead of describing the real dataset. Reviewer #3: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
PONE-D-20-21940R2 CoMA – an intuitive and user-friendly pipeline for amplicon-sequencing data analysis PLOS ONE Dear Mr. Hupfauf, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by 11/30/2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Zechen Chong Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: I am glad that the authors have made a lot changes to their software. I just tested the Singularity version of CoMA v2.0 in this review. Major comment: 1. The authors responded some of my comments by asking me which version of COMA was used and telling me that I should use the latest v2.0 for testing. I used v1.0 because there was only v1.0 could be downloaded from their website before this round of review. I don't think I could test the current v2.0 before this round of revision. Now they have updated their website and added v2.0 download links. 2. The authors used old Singularity version (v2.x). They should clearly mention it in their manual because current Singularity 3.x is quite different from v2.x. The Singularity commands listed in their manual are unavailable in v3.x, such as "singularity image.create". In fact, I think it's better to use Singularity v3.x to build CoMA v2.0. 3. Singularity is good for HPC. As most of the HPCs are accessed by SSH, so the users need to set X11 forwarding to use the GUI from Singularity on remote HPC. Besides, add "-B ~/.Xauthority" parameter to command "singularity shell". It should be mentioned in their manual. Otherwise, the users might be not able to run the CoMA GUI correctly because it's not common to use GUI from Singularity. Besides, it might be more difficult to set this on Mac and Windows. The manual just say that it can be used on MacOS and Windows, but it didn't give any instructions. 4. There might be some problems in the step of renaming samples. For the tutorial, it only shows sample 2 and 3. Sample 1 was missing and it caused errors in downstream analysis. If I chose "Don't rename", then I can get results of downstream analysis. Renaming of samples in progress ... Please enter the new name for each sample: 2: S2 3: S3 Process succeeded! Your samples are renamed now! 5. For my previous comment point 2.4, I meant that CoMA cannot correctly check and handle potential error input of files or parameters. For example, if I input only one FASTQ file from the provided example files, and chose "paired end". It's definitely a naive mistake of user's input, but CoMA pipeline doesn't check this kind of mistakes and it continues. The main terminal was stuck at the "Trimming process proceeding ... " step and the size of detail log file increased with a lot of error message. It's just a very simple problem caused by parameter conflicts. I think CoMA should check the conflicts of parameters and give the users opportunity to re-input the parameters. In current CoMA v2.0, even I found that I just input a wrong parameter in previous step, I cannot change it and I have to stop and re-run the pipeline from the first step. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 3 |
|
CoMA – an intuitive and user-friendly pipeline for amplicon-sequencing data analysis PONE-D-20-21940R3 Dear Sebastian Hupfauf, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Zechen Chong Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-21940R3 CoMA – an intuitive and user-friendly pipeline for amplicon-sequencing data analysis Dear Dr. Hupfauf: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Zechen Chong Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .